Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target
- PMID: 38967581
- PMCID: PMC11227359
- DOI: 10.1097/HC9.0000000000000489
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target
Abstract
HCC is globally recognized as a major health threat. Despite significant progress in the development of treatment strategies for liver cancer, recurrence, metastasis, and drug resistance remain key factors leading to a poor prognosis for the majority of liver cancer patients. Thus, there is an urgent need to develop effective biomarkers and therapeutic targets for HCC. Collagen, the most abundant and diverse protein in the tumor microenvironment, is highly expressed in various solid tumors and plays a crucial role in the initiation and progression of tumors. Recent studies have shown that abnormal expression of collagen in the tumor microenvironment is closely related to the occurrence, development, invasion, metastasis, drug resistance, and treatment of liver cancer, making it a potential therapeutic target and a possible diagnostic and prognostic biomarker for HCC. This article provides a comprehensive review of the structure, classification, and origin of collagen, as well as its role in the progression and treatment of HCC and its potential clinical value, offering new insights into the diagnosis, treatment, and prognosis assessment of liver cancer.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Conflict of interest statement
The authors have no conflicts to report.
Figures


References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
-
- Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PKH, et al. . Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164:766–82. - PubMed
-
- Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. . Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410–20. - PubMed
-
- Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. . Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203–22. - PubMed
-
- European Association For The Study Of The Liver,European Organisation For Research And Treatment Of Cancer EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources